Cargando…

Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology

In the analysis of survival times, the logrank test and the Cox model have been established as key tools, which do not require specific distributional assumptions. Under the assumption of proportional hazards, they are efficient and their results can be interpreted unambiguously. However, delayed tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ristl, Robin, Ballarini, Nicolás M, Götte, Heiko, Schüler, Armin, Posch, Martin, König, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818232/
https://www.ncbi.nlm.nih.gov/pubmed/32830428
http://dx.doi.org/10.1002/pst.2062
_version_ 1783638791860256768
author Ristl, Robin
Ballarini, Nicolás M
Götte, Heiko
Schüler, Armin
Posch, Martin
König, Franz
author_facet Ristl, Robin
Ballarini, Nicolás M
Götte, Heiko
Schüler, Armin
Posch, Martin
König, Franz
author_sort Ristl, Robin
collection PubMed
description In the analysis of survival times, the logrank test and the Cox model have been established as key tools, which do not require specific distributional assumptions. Under the assumption of proportional hazards, they are efficient and their results can be interpreted unambiguously. However, delayed treatment effects, disease progression, treatment switchers or the presence of subgroups with differential treatment effects may challenge the assumption of proportional hazards. In practice, weighted logrank tests emphasizing either early, intermediate or late event times via an appropriate weighting function may be used to accommodate for an expected pattern of non‐proportionality. We model these sources of non‐proportional hazards via a mixture of survival functions with piecewise constant hazard. The model is then applied to study the power of unweighted and weighted log‐rank tests, as well as maximum tests allowing different time dependent weights. Simulation results suggest a robust performance of maximum tests across different scenarios, with little loss in power compared to the most powerful among the considered weighting schemes and huge power gain compared to unfavorable weights. The actual sources of non‐proportional hazards are not obvious from resulting populationwise survival functions, highlighting the importance of detailed simulations in the planning phase of a trial when assuming non‐proportional hazards.We provide the required tools in a software package, allowing to model data generating processes under complex non‐proportional hazard scenarios, to simulate data from these models and to perform the weighted logrank tests.
format Online
Article
Text
id pubmed-7818232
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-78182322021-01-29 Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology Ristl, Robin Ballarini, Nicolás M Götte, Heiko Schüler, Armin Posch, Martin König, Franz Pharm Stat Main Papers In the analysis of survival times, the logrank test and the Cox model have been established as key tools, which do not require specific distributional assumptions. Under the assumption of proportional hazards, they are efficient and their results can be interpreted unambiguously. However, delayed treatment effects, disease progression, treatment switchers or the presence of subgroups with differential treatment effects may challenge the assumption of proportional hazards. In practice, weighted logrank tests emphasizing either early, intermediate or late event times via an appropriate weighting function may be used to accommodate for an expected pattern of non‐proportionality. We model these sources of non‐proportional hazards via a mixture of survival functions with piecewise constant hazard. The model is then applied to study the power of unweighted and weighted log‐rank tests, as well as maximum tests allowing different time dependent weights. Simulation results suggest a robust performance of maximum tests across different scenarios, with little loss in power compared to the most powerful among the considered weighting schemes and huge power gain compared to unfavorable weights. The actual sources of non‐proportional hazards are not obvious from resulting populationwise survival functions, highlighting the importance of detailed simulations in the planning phase of a trial when assuming non‐proportional hazards.We provide the required tools in a software package, allowing to model data generating processes under complex non‐proportional hazard scenarios, to simulate data from these models and to perform the weighted logrank tests. John Wiley & Sons, Inc. 2020-08-23 2021 /pmc/articles/PMC7818232/ /pubmed/32830428 http://dx.doi.org/10.1002/pst.2062 Text en © 2020 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Main Papers
Ristl, Robin
Ballarini, Nicolás M
Götte, Heiko
Schüler, Armin
Posch, Martin
König, Franz
Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
title Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
title_full Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
title_fullStr Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
title_full_unstemmed Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
title_short Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
title_sort delayed treatment effects, treatment switching and heterogeneous patient populations: how to design and analyze rcts in oncology
topic Main Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818232/
https://www.ncbi.nlm.nih.gov/pubmed/32830428
http://dx.doi.org/10.1002/pst.2062
work_keys_str_mv AT ristlrobin delayedtreatmenteffectstreatmentswitchingandheterogeneouspatientpopulationshowtodesignandanalyzerctsinoncology
AT ballarininicolasm delayedtreatmenteffectstreatmentswitchingandheterogeneouspatientpopulationshowtodesignandanalyzerctsinoncology
AT gotteheiko delayedtreatmenteffectstreatmentswitchingandheterogeneouspatientpopulationshowtodesignandanalyzerctsinoncology
AT schulerarmin delayedtreatmenteffectstreatmentswitchingandheterogeneouspatientpopulationshowtodesignandanalyzerctsinoncology
AT poschmartin delayedtreatmenteffectstreatmentswitchingandheterogeneouspatientpopulationshowtodesignandanalyzerctsinoncology
AT konigfranz delayedtreatmenteffectstreatmentswitchingandheterogeneouspatientpopulationshowtodesignandanalyzerctsinoncology